Lu177PSMA617n

Lu177PSMA617n refers to a radiopharmaceutical used in targeted radionuclide therapy for prostate cancer. Specifically, it is Lutetium-177 (Lu-177) conjugated to a prostate-specific membrane antigen (PSMA)-targeting molecule called 617. PSMA is a protein that is highly expressed on the surface of prostate cancer cells, including metastatic and castration-resistant forms. The 617 molecule acts as a delivery vehicle, binding specifically to PSMA on the cancer cells. Once bound, the radioactive isotope Lu-177 emits beta particles. These beta particles have a short range and deliver a cytotoxic dose of radiation directly to the cancer cells, damaging their DNA and leading to cell death. This targeted approach aims to minimize damage to healthy tissues, thereby reducing side effects compared to traditional systemic radiation therapy. Lu177PSMA617n has shown promising results in clinical trials for patients with advanced prostate cancer who have progressed on other treatments. It is administered intravenously and its therapeutic effect is monitored through imaging and clinical response.